oxazoles has been researched along with Medulloblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dismuke, T; Gershon, TR; Hwang, D; Kabanov, AV; Kagel, JR; Lim, C; Ramsey, JD; Rosen, EP; Sokolsky-Papkov PhD, M; Tikunov, A; Zamboni, W | 1 |
| Arcaro, A; Castelletti, D; Fiaschetti, G; Grotzer, M; Hürlimann, ML; Jelesarov, I; Masayuki, T; Nagasawa, K; Shalaby, T; Shin-ya, K; von Bueren, AO | 1 |
2 other study(ies) available for oxazoles and Medulloblastoma
| Article | Year |
|---|---|
Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Topics: Anilides; Animals; Biological Availability; Central Nervous System; Cerebellar Neoplasms; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Medulloblastoma; Mice; Micelles; Nanoparticles; Oxazoles; Particle Size; Protein Binding; Pyridines; Serum Albumin | 2021 |
Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD.
Topics: Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; G-Quadruplexes; Humans; Medulloblastoma; Oxazoles; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-myc; Rhabdoid Tumor; RNA, Messenger; Telomerase; Teratoma; Time Factors | 2010 |